Barchart.com
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Immix Biopharma Inc (IMMX)

Immix Biopharma Inc (IMMX)
1.5200 x 1 1.6400 x 10
Post-market by (Cboe BZX)
1.5650 +0.1020 (+6.97%) 04/11/25 [NASDAQ]
1.5200 x 1 1.6400 x 10
Post-market 1.5650 unch (unch) 15:59 ET
News & Headlines for Fri, Apr 11th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis GlobeNewswire - Mon Feb 10, 8:35AM CST

IMMX : 1.5650 (+6.97%)
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T GlobeNewswire - Tue Jan 7, 8:34AM CST

IMMX : 1.5650 (+6.97%)
Immix Biopharma Reports Promising Initial Clinical Data for NXC-201 in Phase 1b/2 NEXICART-2 Trial for Relapsed/Refractory AL Amyloidosis Quiver Quantitative, Inc. - Thu Dec 19, 2024

Four patients in the NEXICART-2 trial normalized disease markers after NXC-201 treatment, with promising initial responses reported.Quiver AI SummaryImmix Biopharma, Inc. announced positive initial clinical...

IMMX : 1.5650 (+6.97%)
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis GlobeNewswire - Thu Dec 19, 2024

IMMX : 1.5650 (+6.97%)
Immix Biopharma Announces Promising Clinical Results for CAR-T Therapy NXC-201 in Treating Relapsed/Refractory AL Amyloidosis Quiver Quantitative, Inc. - Mon Dec 16, 2024

NXC-201 shows promising efficacy and safety in treating relapsed/refractory AL Amyloidosis, with a 75% complete response rate.Quiver AI SummaryImmix Biopharma, Inc. announced promising results from the...

IMMX : 1.5650 (+6.97%)
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis GlobeNewswire - Mon Dec 16, 2024

IMMX : 1.5650 (+6.97%)
Immix Biopharma Reports 75% Complete Response Rate and 31.5-Month Response Duration for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis at ASH 2024 Quiver Quantitative, Inc. - Tue Dec 10, 2024

Immix Biopharma reports 75% complete response rate for CAR-T NXC-201 in relapsed/refractory AL Amyloidosis patients at ASH 2024.Quiver AI SummaryImmix Biopharma, Inc. reported promising results from its...

IMMX : 1.5650 (+6.97%)
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 GlobeNewswire - Tue Dec 10, 2024

IMMX : 1.5650 (+6.97%)
Immix Biopharma to Host Conference Call on CAR-T NXC-201 Developments for AL Amyloidosis on December 10, 2024 Quiver Quantitative, Inc. - Mon Dec 9, 2024

Immix Biopharma will discuss CAR-T NXC-201 developments in AL Amyloidosis on a December 10 conference call.Quiver AI SummaryImmix Biopharma, Inc. will hold a conference call on December 10, 2024, at 4:30...

IMMX : 1.5650 (+6.97%)
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media GlobeNewswire - Mon Dec 9, 2024

IMMX : 1.5650 (+6.97%)

Barchart Exclusives

This Nvidia-Backed AI Stock Is Shrugging Off Market Pain Thanks to the FDA. Should You Buy Shares Now? Barchart - 1 hour ago
Recursion Pharmaceuticals stock rallied as FDA announces plans of using AI for drug testing. Is it too late to invest in RXRX shares? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
UTC
Reserve Your Spot